Mental Health Research Accelerator Act of 2025
Summary
HR2085 proposes a 25% tax credit for translational research on neurodegenerative and psychiatric conditions, with a $1B aggregate cap in 2026. The bill is in early legislative stage (referred to Ways and Means, zero committee action). The April 18 Executive Order on psychedelic therapies provides a favorable regulatory backdrop but is separate legislation. Pure-play psychedelic/psychiatric biotechs $CMPS, $GHRS, $ATAI are structurally positioned as potential beneficiaries if the bill advances, but the probability of enactment is low at this stage.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR2085 is an early-stage bill with zero committee action since introduction — do not trade this as a near-term catalyst.
- 2.The bill's $1B annual cap is small relative to industry-wide R&D; the credit is most impactful for cash-constrained clinical-stage biotechs, but they cannot use credits without net income unless transferability is added.
- 3.Recent 30-day price surges in $CMPS, $GHRS, and $ATAI are driven by the separate Executive Order on psychedelic therapies, not by this tax legislation.
Market Implications
The market has already priced a favorable regulatory environment for psychedelic therapy developers following the April 18 Executive Order, as reflected in 30-day gains of +51.54% for $CMPS, +38.19% for $GHRS, and +14.97% for $ATAI. However, HR2085 is a separate, early-stage tax bill that offers no near-term catalyst. The 7-day pullbacks suggest the Executive Order rally is consolidating. Until HR2085 advances from committee (unlikely without co-sponsor additions or a Ways and Means markup), investors should treat this as a low-probability tailwind rather than a thesis driver. Pure-play psychiatric biotechs remain structurally tied to regulatory milestones (FDA trial results) and cash runway status, not to early-stage tax credits.
Full Analysis
- WHAT HAPPENED: Representative Mike Thompson (D-CA) introduced HR2085, the Mental Health Research Accelerator Act of 2025, on March 11, 2025. The bill was referred to the House Committee on Ways and Means, where it remains without further action. It has 7 cosponsors. The bill proposes adding Section 45BB to the Internal Revenue Code, creating a 25% tax credit for translational research expenses on neurodegenerative diseases (e.g., Alzheimer's, Parkinson's) and psychiatric conditions (e.g., depression, PTSD, anxiety).
- MONEY TRAIL: This is a tax credit bill — it does NOT authorize or appropriate federal spending. Instead, it reduces the tax liability of companies that conduct qualifying research. The aggregate national cap is $1B for 2026, rising to $2B annually for 2027-2030, then back to $1B for 2031. Credits are allocated via competitive application by the Treasury Secretary in consultation with HHS, FDA, and NIH. Credits can be carried over if the annual cap is not fully subscribed.
- STRUCTURAL WINNERS: Pure-play clinical-stage biotech companies focused on psychiatric conditions — $CMPS, $GHRS, $ATAI — are the most structurally positioned to benefit. These companies have no approved products and thus no taxable income; they cannot utilize tax credits directly unless they can carry them forward or monetize them (e.g., through transferability provisions, which are not specified in the bill). The credit's utility is contingent on future profitability or a transfer market. Large pharmaceutical companies with taxable income (e.g., $PFE, $MRK, $LLY, $JNJ) would be the most capable of using the credit immediately, but the $1B aggregate cap is small relative to their R&D budgets.
- RECENT PRICE ACTION: Over the past 30 days, $CMPS has surged +51.54%, $GHRS +38.19%, and $ATAI +14.97%, largely driven by the April 18 Executive Order on psychedelic therapies. The 7-day trends are negative across the board (-12.53%, -4.05%, -12.1%), suggesting a pullback from post-Executive Order highs. $CMPS at $8.38 is near its 52-week high of $10.21; $GHRS at $19.43 is below its $24.66 high; $ATAI at $4.07 is below its $6.75 high. The market has already repriced on regulatory momentum, but the tax credit bill is distinct and early-stage.
- TIMELINE: HR2085 requires passage by the House Ways and Means Committee, the full House, the Senate (either identical or via amendment), and either reconciliation or a standalone vote. As an early-stage bill with a partisan sponsor (D-CA) and a fiscal cost (tax credit), its path is long and uncertain. The 119th Congress runs through January 2027; if the bill does not advance to markup this year, it will likely not pass. The April 18 Executive Order does not change the bill's legislative status.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
25% tax credit for translational research expenses on neurodegenerative and psychiatric conditions, allocated via competitive application against a $1B aggregate national cap in 2026
Who must act
Taxpayers conducting preclinical-to-clinical translational research on neurodegenerative diseases or psychiatric conditions who apply and are selected by the Treasury Secretary
What happens
Reduces after-tax cost of eligible R&D by 25% for companies that receive an allocation, lowering effective cash burn for translational programs
Stock impact
COMPASS Pathways ($CMPS) is a clinical-stage pure-play developing psilocybin therapy for treatment-resistant depression (a psychiatric condition); the credit directly reduces their translational research costs. With $CMPS trading at $8.38, near its 52-week high of $10.21, the market has already repriced on regulatory momentum from the April 18 Executive Order on psychedelic therapies, but this bill remains early-stage with no guarantee of passage.
What the bill does
25% tax credit for translational research expenses on neurodegenerative and psychiatric conditions, allocated via competitive application against a $1B aggregate national cap in 2026
Who must act
Taxpayers conducting preclinical-to-clinical translational research on neurodegenerative diseases or psychiatric conditions who apply and are selected by the Treasury Secretary
What happens
Reduces after-tax cost of eligible R&D by 25% for companies that receive an allocation, lowering effective cash burn for translational programs
Stock impact
GH Research ($GHRS) is a clinical-stage pure-play developing mebufotenin (5-MeO-DMT) for treatment-resistant depression and other psychiatric conditions; the credit directly subsidizes their translational research costs. At $19.43 per share, the stock remains below its 52-week high of $24.66, with a 30-day upward trend (+38.19%) partially reflecting the favorable regulatory backdrop from the psychedelic therapies Executive Order.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Innovative Therapies Centers of Excellence Act of 2025
Freedom to Heal Act of 2025
Freedom to Heal Act of 2025
Veterans Health Administration Novel Therapeutics Preparedness Act
SUPPORT for Patients and Communities Reauthorization Act of 2025
FERMI FORWARD DISCOVERY GROUP, LLC: $2.5B Department of Energy Contract
MERCK SHARP & DOHME LLC: $2.4B Department of Health and Human Services Contract Vehicle
PA DEPARTMENT OF HUMAN SERVICES: $1.0B Department of Health and Human Services Grant
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Presidential Determination Pursuant to Section 101 of the Defense Production Act of 1950, as Amended, on Recoverable Critical Minerals and Materials
This memorandum invokes the Defense Production Act (DPA) Section 101 to declare that recoverable critical minerals and materials (such as black mass, end-of-life rare-earth magnets, and scrap) are essential to national defense and that the U.S. cannot meet defense needs without disrupting civilian markets. It directs the Secretary of Commerce to issue regulations and take actions—including priority contracts and supply-chain interventions—to rapidly expand domestic recovery and processing of these materials, while explicitly excluding copper scrap already covered by a separate proclamation.
Securing America’s Defense Supply Chains and Ensuring Domestic Acquisition of Critical Materials
This executive order restricts waivers for foreign-sourced critical materials in defense contracts, effective January 1, 2027, and mandates that defense contractors map their supply chains from raw materials to end products, vet subcontractors for risks, and prohibit covered materials from unreliable foreign suppliers. It directs the Secretary of War to enforce strict compliance, including requiring mitigation plans for any non-compliant materials and establishing penalties for fraud or willful noncompliance.
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →